Journal article

Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer

C Gamell, T Gulati, B Solomon, S Haupt, Y Haupt

MOLECULAR & CELLULAR ONCOLOGY | TAYLOR & FRANCIS INC | Published : 2017

Abstract

A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.

Grants

Awarded by Cancer Council Victoria


Awarded by National Health and Medical Research Council


Awarded by Victoria Cancer Agency-Richard Pratt Foundation


Funding Acknowledgements

The work in the authors' laboratory is supported by grants from Cancer Council Victoria's Grant-in-Aid Scheme (1085154), National Health and Medical Research Council (NHMRC 1063389) and a fellowship to CG from Victoria Cancer Agency-Richard Pratt Foundation (Pratt14002).